Biolamina Ab

National University of Singapore

Kristian Tryggvason

Karl Kristian Tryggvason

Yan Wen Yap

Sun Yi

Karl Tryggvason

Outi Hovatta

The present disclosure describes methods of differentiating cardiomyocyte progenitor cells and mature cardiomyocyte cells from pluripotent stem cells. The methods may include differentiating pluripotent stems cells on a substrate including (i) laminin-511 or 521 and (ii) laminin 221. The mature cardiomyocyte cells produced by the method may form a human heart muscle cell line for use in regenerative cardiology.

Differentiation of pluripotent stem cells using laminins LN-511, LN-521 and LN-221

Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221

The present disclosure relates to the use of laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. Methods of enhancing genetic diagnosis by expanding a single stem cell on laminin-521 prior to PCR amplification are disclosed herein.

Methods of enhancing genetic diagnosis

The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.

Stem cell bank

Growing community of inventors

Sundbyberg, Sweden

Kristian Tryggvason